Skip to main content
Premium Trial:

Request an Annual Quote

Precision BioSciences, Cellectis Settle Genome Engineering IP Dispute

NEW YORK (GenomeWeb News) – Precision BioSciences and Cellectis announced Thursday that they have settled patent litigation related to genome engineering technology and have agreed to cross-license certain patents.

The firms have been involved in litigation against each other for several years and they have filed multiple suits against each other over patents covering genome engineering and gene editing technologies.

In May 2013 the US District Court for the District of Delaware found all claims of Cellectis' US Patent No. 7,897,372 that were asserted in a legal action against Precision Bio were invalid. The '372 patent relates to methods of preparing I-CreI meganuclease variants "having a modified cleavage specificity."

Research Triangle Park, NC-based Precision Bio also had sued Paris-based Cellectis asserting 12 of its US patents.

The firms said today that they will cross-license certain genome engineering patents and drop their lawsuits against each other and patent challenges. The agreement provides "clear freedom to operate for both companies in the engineered I-Crel meganuclease genome engineering field," they said in a statement.

Further terms of the settlement were not disclosed.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.